Neoadjuvant and adjuvant strategies for pancreatic cancer

Pancreatic cancer is one of the major causes of cancer death. The majority of patients present with advanced disease and only 10–15% of patients can undergo resection. Survival after curative surgery is poor, as recurrences occur either locally or in the liver. Adjuvant therapy aims to improve survival and control systemic disease. Based on the results from the ESPAC-1 and Oettle studies, there is a significant survival advantage with...